Antrodia for Chronic Inflammatory Conditions

Antrodia Inflammation

6 chronic conditions

Antrodia camphorata compounds have been tested against six distinct chronic inflammatory conditions in preclinical models, reducing TNF-alpha by up to 80% in some assays.

Hseu et al., International Immunopharmacology, 2005

12 studies

across arthritis, colitis, asthma, lupus, skin, vascular

NF-κB suppression

primary mechanism across all conditions

0 human trials

all evidence remains preclinical

Hseu et al., International Immunopharmacology, 2005

View as image ↗

Chronic inflammatory diseases share a common molecular signature: sustained activation of NF-κB, elevated TNF-alpha, IL-6, and IL-1beta, and tissue damage that compounds over months and years. Antrodia camphorata, a parasitic fungus found exclusively on Cinnamomum kanehirae trees in Taiwan, produces triterpenoids and polysaccharides that suppress these same inflammatory cascades in laboratory models of rheumatoid arthritis, colitis, asthma, lupus nephritis, skin ischemia, and atherosclerosis.^[1] For broader context on how Antrodia's triterpenoids drive anti-inflammatory activity, see Antrodia and inflammation: anti-inflammatory triterpenoid research.

None of these findings come from human clinical trials. Every study described here used cell cultures or animal models. That distinction matters because compounds that suppress inflammation in a mouse joint or a cultured macrophage often fail when tested in people, where drug metabolism, dosing, and disease complexity intervene.

Six Conditions, One Shared Target

Broad Across Diseases, But Every Row Is Preclinical

Antrodia camphorata compounds have been tested against six distinct chronic inflammatory conditions, and nearly every one traces back to the same molecular lever — suppression of NF-κB and its downstream cytokines. Reading down the strength column shows the real shape of the evidence: wide across conditions, but thin per condition, and animal- or cell-only throughout. There are zero human trials for any of these conditions.

Rheumatoid arthritis

Strongest evidence · 3 studies · one lab

Human cells + in-vivo

Compounds

Antcin K

Model

Human RA synovial fibroblasts + collagen-induced arthritis mice

Refs

[2] [3] [4]

Lupus nephritis

Moderate evidence · 1 study

Chronic in-vivo model

Compounds

Mycelia extract (crude)

Model

Spontaneous autoimmune NZB/W F1 mice

Refs

[8]

Asthma

Moderate evidence · 1 study (+ mechanism)

In-vitro + in-vivo

Compounds

GF2 polysaccharide · antrodan glycoprotein

Model

Ovalbumin-sensitized mice + bone-marrow dendritic cells

Refs

[6] [7]

Atherosclerosis

Moderate evidence · 1 study

In-vitro + in-vivo

Compounds

Fermented extract

Model

Vascular smooth muscle cells + ApoE-deficient mice

Refs

[10]

Colitis (IBD model)

Weakest evidence · 1 study

Single acute model

Compounds

Ethanol extract (crude)

Model

DSS-induced colitis mice — acute, not chronic-relapsing

Refs

[5]

Skin ischemia

Weakest evidence · 1 study

Single acute model

Compounds

Ergostatrien-3β-ol · whole extract

Model

Dorsal skin-flap ischemia-reperfusion mice — acute injury

Refs

[9]

The rheumatoid-arthritis row is the deepest but comes entirely from a single research group studying one compound (antcin K) in one cell type; independent replication has not been published. The remaining five conditions rest on a single study each. Broader mechanism work — carrageenan edema with eburicoic and dehydroeburicoic acid (Deng 2013 [12]) and a catalogue of 200+ terpenoid structures (Kuang 2021 [13]) — supports the NF-κB story but does not add human evidence.

Evidence synthesis; cells from refs [1]–[13] (see references)

Rheumatoid arthritis: antcin K targets multiple RA pathways

Rheumatoid arthritis involves chronic synovial inflammation that destroys cartilage and bone. Achudhan et al. (2021) tested antcin K, a triterpenoid from Antrodia cinnamomea fruiting bodies, against this process in both cell culture and animal models.^[2]

In human rheumatoid arthritis synovial fibroblasts (RASFs), the cells that drive joint destruction, antcin K suppressed production of TNF-alpha, IL-1beta, and IL-8. The mechanism traced through FAK, PI3K, AKT, and NF-κB signaling cascades.^[2] In collagen-induced arthritis mice, intraperitoneal antcin K injections attenuated paw swelling, cartilage degradation, and bone erosion while decreasing serum inflammatory markers.

Two follow-up studies expanded the picture. Achudhan et al. (2022) showed that antcin K inhibited VCAM-1-dependent monocyte adhesion in RASFs, a process that recruits immune cells into the inflamed joint.^[3] Separately, antcin K suppressed VEGF-dependent angiogenesis in RASFs by downregulating the phospholipase C-gamma/protein kinase C-alpha pathway, targeting the blood vessel growth that feeds inflamed synovial tissue.^[4]

The RA research is the most developed of any chronic inflammatory condition for Antrodia. Three published studies from the same research group cover cytokine suppression, immune cell recruitment, and angiogenesis. The limitation is that all three involve the same compound (antcin K), the same cell type (RASFs), and the same research team. Independent replication from other laboratories has not been published. For deeper analysis of antcin K's NF-κB pathway effects, see Antcin K and NF-κB inhibition.

Colitis: suppressing intestinal inflammation in mice

Park et al. (2013) tested an ethanol extract of Antrodia camphorata grown on germinated brown rice in dextran sulfate sodium (DSS)-induced colitis mice, a standard model of ulcerative colitis.^[5]

The extract attenuated disease severity across multiple endpoints. Disease activity index scores improved, colon shortening was reduced, and myeloperoxidase activity (a marker of neutrophil infiltration) decreased in colonic tissue. Histological analysis showed reduced mucosal damage, crypt loss, and inflammatory cell infiltration in the colon wall.^[5]

At the molecular level, the extract suppressed expression of TNF-alpha, IL-1beta, IL-6, iNOS, and COX-2 in colonic tissue. These are the same inflammatory mediators targeted by conventional IBD therapies like anti-TNF biologics and JAK inhibitors, though the mechanism of suppression differs.

This is a single study using one extract preparation in one colitis model. DSS-induced colitis models acute inflammation rather than the chronic, relapsing pattern of human ulcerative colitis or Crohn's disease. The extract was also a complex mixture grown on a specific substrate (germinated brown rice), making it difficult to identify which compounds drove the effect.

The colitis findings are particularly interesting in context because the molecular targets suppressed by the Antrodia extract (TNF-alpha, IL-1beta, IL-6) are the same cytokines targeted by biologic drugs currently used in IBD treatment. Anti-TNF agents like infliximab and adalimumab have transformed ulcerative colitis management. Whether Antrodia compounds could achieve similar cytokine suppression at the gut mucosal level in humans, and at what dose, remains completely unknown.

Asthma: polysaccharides shift immune balance

Liu et al. (2010) investigated a polysaccharide fraction called GF2 from Antrodia camphorata submerged culture in an ovalbumin-induced asthma mouse model.^[6]

GF2 worked through dendritic cells, the immune cells that shape T cell responses. In bone marrow-derived dendritic cells stimulated with lipopolysaccharide, GF2 enhanced production of IL-10 (anti-inflammatory) and IL-12 (Th1-promoting) while suppressing naive CD4+ T cell proliferation and Th2 polarization.^[6]

In the animal model, higher doses of GF2 dose-dependently inhibited airway hyperresponsiveness to methacholine challenge. Bronchoalveolar lavage showed reduced total cell counts and eosinophilia, with decreased Th2 cytokines (IL-4, IL-5, IL-13) and increased Th1 cytokines (IFN-gamma).^[6] Serum IgE levels also dropped.

This immune-shifting mechanism is distinct from the triterpenoid-driven NF-κB suppression seen in other Antrodia inflammation studies. GF2 is a polysaccharide, not a triterpenoid, suggesting Antrodia contains at least two structurally different anti-inflammatory compound classes working through separate pathways. The antrodan glycoprotein isolated by Chiu et al. (2013) represents yet another structurally distinct anti-inflammatory fraction from Antrodia mycelia.^[7]

Compound diversity: triterpenoids vs. polysaccharides vs. glycoproteins

A recurring theme across these studies is that different compound classes from Antrodia camphorata suppress inflammation through different mechanisms. The triterpenoids (antcin K, eburicoic acid, dehydroeburicoic acid, ergostatrien-3beta-ol) primarily target NF-κB signaling to reduce cytokine production. The polysaccharides (GF2 fraction) act through dendritic cell modulation to shift T helper cell balance. The glycoprotein antrodan, characterized by Chiu et al. (2013), suppressed NO and prostaglandin E2 production in macrophages through yet another mechanism involving its high uronic acid content.^[7]

This diversity matters because crude Antrodia extracts contain all three compound classes simultaneously. A fermented broth or mycelial extract could theoretically suppress inflammation through multiple parallel pathways, which may explain why whole extracts sometimes show stronger effects than isolated compounds in direct comparisons. It also means that studies using different extract preparations may be studying fundamentally different pharmacological activities. For the full bioactive compound landscape, see Antrodia bioactive compounds: antcins, triterpenoids, and polysaccharides.

Lupus nephritis: slowing autoimmune kidney damage

Chang et al. (2011) tested an Antrodia camphorata mycelia extract in NZB/W F1 mice, a spontaneous lupus model where female mice develop anti-dsDNA antibodies, proteinuria, and immune complex glomerulonephritis similar to human systemic lupus erythematosus.^[8]

Oral administration of the extract beginning at 16 weeks of age (before disease onset) extended median survival compared to untreated controls. Treated mice showed reduced proteinuria, lower serum anti-dsDNA antibody titers, and decreased immune complex deposition in glomeruli.^[8] Renal histology showed less glomerular proliferation and tubular damage.

The lupus model is notable because it involves spontaneous autoimmunity rather than chemically induced inflammation. The progressive, multisystem nature of lupus in NZB/W F1 mice more closely mirrors human chronic inflammatory disease than acute models like DSS colitis or carrageenan edema. However, this is a single study with a crude extract, and the active compounds responsible for the effect were not identified.

Skin and vascular inflammation: tissue-specific protection

Two studies tested Antrodia compounds in chronic inflammatory contexts outside joints and the gut.

Skin ischemia

Tsai et al. (2015) used a dorsal skin flap model in mice to create ischemia-reperfusion injury, which triggers an inflammatory cascade involving neutrophil infiltration, ROS production, and cytokine release.^[9]

Oral pretreatment with Antrodia camphorata extract and its isolated compound ergostatrien-3beta-ol reduced skin flap necrosis and inflammatory cell infiltration. Expression of iNOS, IL-6, TNF-alpha, and NF-κB decreased in treated animals. The protective effect was dose-dependent, with higher extract concentrations showing greater necrosis reduction.^[9]

Atherosclerosis

Yang et al. (2017) examined Antrodia camphorata's effects on cigarette smoke-induced vascular inflammation, a driver of atherosclerosis.^[10]

In cultured vascular smooth muscle cells exposed to cigarette smoke extract, the fermented Antrodia extract reduced ROS production, DNA damage, apoptosis, and inflammatory cytokine expression. The protective mechanism involved upregulation of heme oxygenase-1 (HO-1) and other Nrf2-dependent antioxidant enzymes.^[10]

In ApoE-deficient mice (a genetic atherosclerosis model), oral Antrodia administration prevented cigarette smoke-accelerated plaque formation while improving serum cholesterol and triglyceride levels. This study connects Antrodia's anti-inflammatory activity to cardiovascular protection, though the clinical relevance of an orally administered mushroom extract for human atherosclerosis prevention remains entirely speculative. For related vascular research, see Antrodia and antioxidant activity: free radical protection.

The shared mechanism: NF-κB as the common target

Across these six conditions, one pathway appears repeatedly: NF-κB. Hseu et al. (2005) published the first in vitro confirmation that Antrodia camphorata suppresses NF-κB activation by blocking IkappaB-alpha degradation in LPS-stimulated macrophages.^[1] Subsequent studies in arthritis, skin, and vascular models identified the same target.

Tung et al. (2014) demonstrated this using NF-κB/luciferase transgenic mice, providing real-time visualization of NF-κB suppression. Both solid-state-cultured and wood-cultured Antrodia extracts reduced NF-κB-driven bioluminescence in hyperoxia-induced lung injury, with eburicoic acid and dehydroeburicoic acid identified as major bioactive triterpenoids.^[11]

Deng et al. (2013) confirmed these triterpenoids' anti-inflammatory effects in carrageenan-induced paw edema, showing decreased iNOS and COX-2 expression alongside reduced TNF-alpha and IL-1beta levels, with increased antioxidant enzyme activities (catalase, superoxide dismutase, glutathione peroxidase).^[12]

Kuang et al. (2021) catalogued over 200 terpenoid structures from Antrodia camphorata in their comprehensive review, noting that lanostane triterpenoids form the largest and most pharmacologically active class, with anti-inflammatory activity among the most consistently documented properties.^[13]

NF-κB is also the primary target of many approved anti-inflammatory drugs, including corticosteroids and certain biologics. The difference is dose precision. Pharmaceutical NF-κB inhibitors are dosed at specific concentrations with known pharmacokinetics. Antrodia extracts contain variable concentrations of multiple NF-κB-active compounds, making dose-response relationships unpredictable in humans. For detailed pathway analysis, see Antrodia and neuroinflammation: brain protection research.

What the evidence does not show

Preclinical anti-inflammatory activity does not predict clinical efficacy. Several specific gaps apply to the Antrodia chronic inflammation literature:

No human trials exist. Zero randomized controlled trials have tested Antrodia camphorata for rheumatoid arthritis, inflammatory bowel disease, asthma, lupus, or any other chronic inflammatory condition. The entire evidence base is cell culture and animal models.

Extract standardization is absent. Studies use different Antrodia preparations: fermented culture broth, ethanol extracts of mycelia grown on germinated brown rice, solid-state-cultured mycelia, wood-cultured fruiting bodies, and isolated individual compounds. Results from one preparation do not automatically apply to another. This matters because the bioactive compound profile varies dramatically between cultivation methods, as Tung et al. (2014) demonstrated.^[11]

Pharmacokinetics are unknown. Oral bioavailability of Antrodia triterpenoids in humans has not been established. A compound that suppresses NF-κB in a cell culture assay may be degraded in the gut, fail to reach target tissues, or require doses that produce side effects.

Dose translation is uncertain. Mouse doses do not directly translate to human equivalents. The body surface area conversion factor between mice and humans is roughly 12.3, but this does not account for differences in absorption, distribution, metabolism, and excretion.

Publication bias favors positive results. The published Antrodia inflammation literature is overwhelmingly positive. Negative or null results are less likely to be published, potentially inflating the apparent efficacy of these compounds. Related drug interaction concerns are discussed in Antrodia and drug interactions: what to know.

This article summarizes preclinical research and is not medical advice. No human safety or efficacy data exist for Antrodia camphorata in rheumatoid arthritis, inflammatory bowel disease, asthma, lupus, or any other chronic inflammatory condition. Anyone considering Antrodia for an inflammatory or autoimmune disease should consult a qualified clinician before use, particularly because it has documented potential for drug interactions and no established human dose.

The Bottom Line

Antrodia camphorata compounds, particularly antcin K and eburicoic acid, suppress inflammatory markers in preclinical models of six chronic conditions: rheumatoid arthritis, colitis, asthma, lupus nephritis, skin ischemia, and atherosclerosis. NF-κB pathway inhibition appears to be the shared mechanism. The rheumatoid arthritis data is the most developed, with three published studies covering cytokine suppression, immune cell recruitment, and angiogenesis. Every study remains preclinical, with zero human clinical trials for any chronic inflammatory condition and no standardized extract preparation.

Frequently Asked Questions

Does Antrodia camphorata reduce inflammation?

Antrodia camphorata extracts and isolated triterpenoids reduce inflammatory markers including TNF-alpha, IL-6, IL-1beta, iNOS, and COX-2 in cell culture and animal models. The primary mechanism is NF-κB pathway suppression, first demonstrated by Hseu et al. (2005) in LPS-stimulated macrophages. No human clinical trials have tested anti-inflammatory effects in people with chronic inflammatory diseases.

Can Antrodia help with rheumatoid arthritis?

Antcin K from Antrodia cinnamomea reduced paw swelling, cartilage degradation, and bone erosion in collagen-induced arthritis mice (Achudhan et al., 2021). The compound also inhibited monocyte adhesion and angiogenesis in human rheumatoid synovial fibroblasts. All evidence is preclinical from a single research group, and no human RA trials have been published.

What are Antrodia camphorata's anti-inflammatory compounds?

Antrodia produces multiple anti-inflammatory compound classes. Triterpenoids including antcin K, eburicoic acid, dehydroeburicoic acid, and ergostatrien-3beta-ol suppress NF-κB signaling. Polysaccharides like the GF2 fraction modulate dendritic cell function and shift Th2/Th1 immune balance. The glycoprotein antrodan also shows anti-inflammatory activity. Kuang et al. (2021) catalogued over 200 terpenoid structures from this single fungal species.

Is Antrodia camphorata good for autoimmune diseases?

One preclinical study tested Antrodia mycelia extract in lupus-prone NZB/W F1 mice, showing extended survival, reduced proteinuria, and decreased anti-dsDNA antibodies (Chang et al., 2011). Antcin K research in rheumatoid arthritis models also shows immunomodulatory effects. No human studies have tested Antrodia for any autoimmune condition, and preclinical results frequently fail to translate to clinical benefit.

How does Antrodia camphorata fight inflammation?

The dominant mechanism is suppression of NF-κB signaling. Antrodia triterpenoids block IkappaB-alpha degradation, preventing NF-κB from entering the cell nucleus and activating inflammatory gene transcription. This reduces downstream production of TNF-alpha, IL-6, IL-1beta, iNOS, and COX-2. A secondary mechanism involves polysaccharide-mediated dendritic cell modulation, which shifts immune responses from pro-inflammatory Th2 toward Th1 balance, as demonstrated in asthma models (Liu et al., 2010).

Is Antrodia camphorata good for colitis or IBD?

An ethanol extract of Antrodia camphorata reduced disease severity in DSS-induced colitis mice, decreasing inflammatory cell infiltration and suppressing TNF-alpha, IL-1beta, and IL-6 in colonic tissue (Park et al., 2013). This is a single study using an acute colitis model, which does not capture the chronic relapsing pattern of human IBD. No human studies exist for Antrodia in inflammatory bowel disease.

Sources & References

1. 1RTHM-00079·Hseu, You-Cheng et al. (2005). “Anti-inflammatory potential of Antrodia Camphorata through inhibition of iNOS, COX-2 and cytokines via the NF-kappaB pathway..” International immunopharmacology.Study breakdown →PubMed →↩
2. 2RTHM-00670·Achudhan, David et al. (2021). “Antcin K Inhibits TNF-α, IL-1β and IL-8 Expression in Synovial Fibroblasts and Ameliorates Cartilage Degradation: Implications for the Treatment of Rheumatoid Arthritis..” Frontiers in immunology.Study breakdown →PubMed →↩
3. 3RTHM-00738·Achudhan, David et al. (2022). “Antcin K inhibits VCAM-1-dependent monocyte adhesion in human rheumatoid arthritis synovial fibroblasts..” Food & nutrition research.Study breakdown →PubMed →↩
4. 4RTHM-00739·Achudhan, David et al. (2022). “Antcin K inhibits VEGF-dependent angiogenesis in human rheumatoid arthritis synovial fibroblasts..” Journal of food biochemistry.Study breakdown →PubMed →↩
5. 5RTHM-00302·Park, Dong Ki et al. (2013). “Ethanol Extract of Antrodia camphorata Grown on Germinated Brown Rice Suppresses Inflammatory Responses in Mice with Acute DSS-Induced Colitis..” Evidence-based complementary and alternative medicine : eCAM.Study breakdown →PubMed →↩
6. 6RTHM-00192·Liu, Ko-Jiunn et al. (2010). “Administration of polysaccharides from Antrodia camphorata modulates dendritic cell function and alleviates allergen-induced T helper type 2 responses in a mouse model of asthma..” Immunology.Study breakdown →PubMed →↩
7. 7RTHM-00282·Chiu, Chun-Hung et al. (2013). “Physicochemical characteristics and anti-inflammatory activities of antrodan, a novel glycoprotein isolated from Antrodia cinnamomea mycelia..” Molecules (Basel.Study breakdown →PubMed →↩
8. 8RTHM-00206·Chang, Jia-Ming et al. (2011). “An Extract of Antrodia camphorata Mycelia Attenuates the Progression of Nephritis in Systemic Lupus Erythematosus-Prone NZB/W F1 Mice..” Evidence-based complementary and alternative medicine : eCAM.Study breakdown →PubMed →↩
9. 9RTHM-00406·Tsai, Tung-Chou et al. (2015). “Anti-inflammatory effects of Antrodia camphorata, a herbal medicine, in a mouse skin ischemia model..” Journal of ethnopharmacology.Study breakdown →PubMed →↩
10. 10RTHM-00500·Yang, Hsin-Ling et al. (2017). “Antrodia camphorata attenuates cigarette smoke-induced ROS production, DNA damage, apoptosis, and inflammation in vascular smooth muscle cells, and atherosclerosis in ApoE-deficient mice..” Environmental toxicology.Study breakdown →PubMed →↩
11. 11RTHM-00353·Tung, Yu-Tang et al. (2014). “Comparison of solid-state-cultured and wood-cultured Antrodia camphorata in anti-inflammatory effects using NF-κB/luciferase inducible transgenic mice..” Phytomedicine : international journal of phytotherapy and phytopharmacology.Study breakdown →PubMed →↩
12. 12RTHM-00284·Deng, Jeng-Shyan et al. (2013). “Analgesic and anti-inflammatory bioactivities of eburicoic acid and dehydroeburicoic acid isolated from Antrodia camphorata on the inflammatory mediator expression in mice..” Journal of agricultural and food chemistry.Study breakdown →PubMed →↩
13. 13RTHM-00695·Kuang, Yi et al. (2021). “Terpenoids from the medicinal mushroom Antrodia camphorata: chemistry and medicinal potential..” Natural product reports.Study breakdown →PubMed →↩